Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country by Mahdieh Fathi, Najmeh Moradi, Nazila Yousefi, Farzad Peiravian, Nikta Shobeiri

“…Methods The affordability of medicines in mono and combination therapy approaches was assessed in CRDs using the World Health Organization/Health Action International (WHO/HAI) methodology. Accordingly, if out-of-pocket payment for 30-days of pharmacotherapy exceeds one day for the lowest-paid unskilled government worker (LPGW), it’s considered non-affordable. …”
Get full text

Affordability of Medication Therapy in Diabetic Patients: A Scenario-Based Assessment in Iran’s Health System Context by Leila Zarei, Payam Peymani, Najmeh Moradi, Mehrnaz Kheirandish, Mahtabalsadat Mirjalili, Marziyeh Zare

“…Then the affordability ratio of each treatment scenario was determined for type 1 and type 2 diabetes drawing on the World Health Organization (WHO)/Health Action International (HAI) Methodology. If the affordability ratio for treatment schedules was more than 1, the patients’ out-of-pocket (OOP) expenses exceeded the lowest-paid unskilled government worker (LPGW)’ wage per day, and the treatment was labelled as non-affordable. …”
Get full text